恒瑞醫藥(600276.SH):擬將GLP-1產品組合有償許可給美國Hercules公司
格隆匯5月16日丨恒瑞醫藥(600276.SH)公佈,公司將具有自主知識產權的GLP-1產品組合有償許可給美國Hercules公司,美國Hercules公司將獲得在除大中華區以外的全球範圍內開發、生產和商業化GLP-1產品組合的獨家權利。作為對外許可交易對價一部分,恒瑞將取得美國Hercules公司19.9%的股權,且將從美國Hercules公司獲得GLP-1產品組合授權許可費。
GLP-1產品組合是恒瑞自主研發的針對糖尿病、肥胖及其它代謝性疾病的創新藥,包括:(1)HRS-7535,小分子GLP-1受體激動劑;(2)HRS9531,多肽GLP-1/GIP雙受體激動劑注液和口服產品;(3)HRS-4729,下一代腸促胰島素產品。
首付款和近期里程碑總計1.1億美元,其中包括1億美元的首付款和完成技術轉移後的1000萬美元的近期里程碑付款。基於HRS-7535臨牀開發進度及FDA首次獲批上市,美國Hercules公司將向恒瑞支付累計不超過2億美元的臨牀開發及監管里程碑款。基於GLP-1產品組合在許可區域實際年淨銷售額情況,美國Hercules公司將向恒瑞支付累計不超過57.25億美元的銷售里程碑款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.